NK-1 receptor antagonists
作者： Andreas Koblet , Christoph Funk , Torsten Hoffmann
DOI:
关键词:
摘要: The present invention relates to compounds of formula I wherein R is methyl; and R1 4-methyl-4-oxy-piperazin-1-yl; or CH2OH 4-methyl-piperazin-1-yl pharmaceutically acceptable acid addition salts thereof for the treatment NK-1 receptor related diseases, example depression, Parkinson's disease, Alzheimer's anxiety, emesis, pain.
lens.org参考文章(13)
Paul E. Finke, Malcolm MacCoss, Jeffrey J. Hale, Sander G. Mills, Brian John Williams, Shrenik K. Shah, Tamara Ladduwahetty, Mark Stuart Chambers, Conrad P. Dorn, Timothy Harrison, Morpholine and thiomorpholine tachykinin receptor antagonists ,(1993)
Thierry Godel, Walter Hunkeler, Guido Galley, Patrick Schnider, Michael Bös, Heinz Stadler, Quirico Branca, Torsten Hoffmann, 4-phenyl-pyridine derivatives ,(2000)
Andrew Sleight, Sonia Maria Poli, Theresa Maria Ballard, Torsten Hoffmann, Guy Andrew Higgins, 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide ,(2000)
Thierry Godel, Walter Hunkeler, Guido Galley, Michael Montreal Boes, Patrick Schnider, Heinz Stadler, Quirico Branca, Torsten Hoffmann, 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists ,(2000)
Patrick Schnider, Heinz Stadler, Michael Boes, Guido Galley, Quirico Branca, Thierry Godel, Walter Hunkeler, Torsten Hoffmann, Neurokinin-1-Rezeptorantagonisten ,(2000)
Graham S. Poindexter, Marc Bruce, Scott W. Martin, Sing-Yuen Sit, Alkylamine derivatives of dihydropyridine npy antagonists ,(2001)
Nadia Rupniak, Mark S. Kramer, Method for treating or preventing psychoimmunological disorders ,(1998)
Alan Nimmo, Robert Vink, Torsten Hoffmann, Andrew Sleight, Pierre Vankan, Method of treatment and/or prevention of brain, spinal or nerve injury ,(2006)
Andreas Koblet, Jens-Uwe Peters, Patrick Schnider, Andrew Sleight, Heinz Stadler, Torsten Hoffmann, Dual nk1/nk3 receptor antagonists ,(2009)
Patrick Schnider, Andrew Sleight, Sonia Maria Poli, Torsten D. Hoffmann, NK-1 receptor active amine oxide prodrugs ,(2003)